Kroeger PT, Jr., Drapkin R: Pathogenesis and heterogeneity of ovarian cancer. Curr Opin Obstet Gynecol 2017, 29(1):26-34.
 Siegel RL, Miller KD, Jemal A: Cancer statistics, 2019. CA Cancer J Clin 2019, 69(1):7-34.
 Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al: Ovarian cancer statistics, 2018. CA Cancer J Clin 2018, 68(4):284-296.
 Lee HH, Bellat V, Law B: Chemotherapy induces adaptive drug resistance and metastatic potentials via phenotypic CXCR4-expressing cell state transition in ovarian cancer. PLoS One 2017, 12(2):e0171044.
 Domingues C, Serambeque BP, Laranjo Candido MS, Marto CMM, Veiga FJB, Sarmento Antunes Cruz Ribeiro AB, et al: Epithelial-mesenchymal transition and microRNAs: Challenges and future perspectives in oral cancer. Head Neck 2018, 40(10):2304-2313.
 Samuel P, Carter DR: The Diagnostic and Prognostic Potential of microRNAs in Epithelial Ovarian Carcinoma. Mol Diagn Ther 2017, 21(1):59-73.
 Moga MA, Balan A, Dimienescu OG, Burtea V, Dragomir RM, Anastasiu CV: Circulating miRNAs as Biomarkers for Endometriosis and Endometriosis-Related Ovarian Cancer-An Overview. J Clin Med 2019, 8(5).
 Muhammad N, Bhattacharya S, Steele R, Ray RB: Anti-miR-203 suppresses ER-positive breast cancer growth and stemness by targeting SOCS3. Oncotarget 2016, 7(36):58595-58605.
 Wang S, Zhang G, Zheng W, Xue Q, Wei D, Zheng Y, et al: MiR-454-3p and miR-374b-5p suppress migration and invasion of bladder cancer cells through targetting ZEB2. Biosci Rep 2018, 38(6).
 Li J, Liang Y, Lv H, Meng H, Xiong G, Guan X, et al: miR-26a and miR-26b inhibit esophageal squamous cancer cell proliferation through suppression of c-MYC pathway. Gene 2017, 625:1-9.
 Pak E, Segal RA: Hedgehog Signal Transduction: Key Players, Oncogenic Drivers, and Cancer Therapy. Dev Cell 2016, 38(4):333-344.
 Du B, Shim JS: Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer. Molecules 2016, 21(7).
 Suarez-Carmona M, Lesage J, Cataldo D, Gilles C: EMT and inflammation: inseparable actors of cancer progression. Mol Oncol 2017, 11(7):805-823.
 Guan X, Ma F, Li C, Wu S, Hu S, Huang J, et al: The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer. Cancer Commun (Lond) 2019, 39(1):1.
 Alimirah F, Peng X, Gupta A, Yuan L, Welsh J, Cleary M, et al: Crosstalk between the vitamin D receptor (VDR) and miR-214 in regulating SuFu, a hedgehog pathway inhibitor in breast cancer cells. Exp Cell Res 2016, 349(1):15-22.
 Li J, Qiu M, An Y, Huang J, Gong C: miR-7-5p acts as a tumor suppressor in bladder cancer by regulating the hedgehog pathway factor Gli3. Biochem Biophys Res Commun 2018, 503(3):2101-2107.
 Wen SY, Lin Y, Yu YQ, Cao SJ, Zhang R, Yang XM, et al: miR-506 acts as a tumor suppressor by directly targeting the hedgehog pathway transcription factor Gli3 in human cervical cancer. Oncogene 2015, 34(6):717-725.
 Mohammad N, Singh SV, Malvi P, Chaube B, Athavale D, Vanuopadath M, et al: Strategy to enhance efficacy of doxorubicin in solid tumor cells by methyl-beta-cyclodextrin: Involvement of p53 and Fas receptor ligand complex. Sci Rep 2015, 5:11853.
 Muhammad N, Steele R, Isbell TS, Philips N, Ray RB: Bitter melon extract inhibits breast cancer growth in preclinical model by inducing autophagic cell death. Oncotarget 2017, 8(39):66226-66236.
 Muhammad N, Bhattacharya S, Steele R, Phillips N, Ray RB: Involvement of c-Fos in the Promotion of Cancer Stem-like Cell Properties in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 2017, 23(12):3120-3128.
 Bai J, Xu J, Zhao J, Zhang R: lncRNA SNHG1 cooperated with miR-497/miR-195-5p to modify epithelial-mesenchymal transition underlying colorectal cancer exacerbation. J Cell Physiol 2020, 235(2):1453-1468.
 Wang YF, Yang HY, Shi XQ, Wang Y: Upregulation of microRNA-129-5p inhibits cell invasion, migration and tumor angiogenesis by inhibiting ZIC2 via downregulation of the Hedgehog signaling pathway in cervical cancer. Cancer Biol Ther 2018, 19(12):1162-1173.
 Chaudary N, Pintilie M, Hedley D, Hill RP, Milosevic M, Mackay H: Hedgehog inhibition enhances efficacy of radiation and cisplatin in orthotopic cervical cancer xenografts. Br J Cancer 2017, 116(1):50-57.
 Bhat A, Sharma A, Bharti AC: Upstream Hedgehog signaling components are exported in exosomes of cervical cancer cell lines. Nanomedicine (Lond) 2018, 13(17):2127-2138.
 Han W, Allam SA, Elsawa SF: GLI2-Mediated Inflammation in the Tumor Microenvironment. Adv Exp Med Biol 2020, 1263:55-65.
 Wang N, Li P, Liu W, Wang N, Lu Z, Feng J, et al: miR-141-3p suppresses proliferation and promotes apoptosis by targeting GLI2 in osteosarcoma cells. Oncol Rep 2018, 39(2):747-754.
 Zhang Y, Chen Z, Li MJ, Guo HY, Jing NC: Long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 regulates the expression of Gli2 by miR-202 to strengthen gastric cancer progression. Biomed Pharmacother 2017, 85:264-271.
 Rupaimoole R, Slack FJ: MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov 2017, 16(3):203-222.
 Khan AQ, Ahmed EI, Elareer NR, Junejo K, Steinhoff M, Uddin S: Role of miRNA-Regulated Cancer Stem Cells in the Pathogenesis of Human Malignancies. Cells 2019, 8(8).
 Hu QL, Xu ZP, Lan YF, Li B: miR-636 represses cell survival by targeting CDK6/Bcl-2 in cervical cancer. Kaohsiung J Med Sci 2020, 36(5):328-335.
 Chen CL, Lin CH, Li AL, Huang CC, Shen BY, Chiang YR, et al: Plasma miRNA profile is a biomarker associated with urothelial carcinoma in chronic hemodialysis patients. Am J Physiol Renal Physiol 2019, 316(6):F1094-F1102.
 Pashaei E, Pashaei E, Ahmady M, Ozen M, Aydin N: Meta-analysis of miRNA expression profiles for prostate cancer recurrence following radical prostatectomy. PLoS One 2017, 12(6):e0179543.
 Jiang J, Hui CC: Hedgehog signaling in development and cancer. Dev Cell 2008, 15(6):801-812.
 Lum L, Beachy PA: The Hedgehog response network: sensors, switches, and routers. Science 2004, 304(5678):1755-1759.
 Tang YA, Chen YF, Bao Y, Mahara S, Yatim S, Oguz G, et al: Hypoxic tumor microenvironment activates GLI2 via HIF-1alpha and TGF-beta2 to promote chemoresistance in colorectal cancer. Proc Natl Acad Sci U S A 2018, 115(26):E5990-E5999.
 Huang D, Wang Y, Xu L, Chen L, Cheng M, Shi W, et al: GLI2 promotes cell proliferation and migration through transcriptional activation of ARHGEF16 in human glioma cells. J Exp Clin Cancer Res 2018, 37(1):247.
 Zhu H, Xia L, Shen Q, Zhao M, Gu X, Bouamar H, et al: Differential effects of GLI2 and GLI3 in regulating cervical cancer malignancy in vitro and in vivo. Lab Invest 2018, 98(11):1384-1396.
 Raven PA, Lysakowski S, Tan Z, D'Costa NM, Moskalev I, Frees S, et al: Inhibition of GLI2 with antisense-oligonucleotides: A potential therapy for the treatment of bladder cancer. J Cell Physiol 2019, 234(11):20634-20647.
 Chun HW, Hong R: Significance of the hedgehog pathway-associated proteins Gli-1 and Gli-2 and the epithelial-mesenchymal transition-associated proteins Twist and E-cadherin in hepatocellular carcinoma. Oncol Lett 2016, 12(3):1753-1762.
 Adams CR, Htwe HH, Marsh T, Wang AL, Montoya ML, Subbaraj L, et al: Transcriptional control of subtype switching ensures adaptation and growth of pancreatic cancer. Elife 2019, 8.
 Sun M, Zhang N, Wang X, Li Y, Qi W, Zhang H, et al: Hedgehog pathway is involved in nitidine chloride induced inhibition of epithelial-mesenchymal transition and cancer stem cells-like properties in breast cancer cells. Cell Biosci 2016, 6:44.
 He Q, Huang L, Yan D, Bi J, Yang M, Huang J, et al: CircPTPRA acts as a tumor suppressor in bladder cancer by sponging miR-636 and upregulating KLF9. Aging (Albany NY) 2019, 11(23):11314-11328.